Thompson Siegel & Walmsley LLC Sells 76,365 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Thompson Siegel & Walmsley LLC lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 601,515 shares of the medical equipment provider’s stock after selling 76,365 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Zimmer Biomet were worth $54,088,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ZBH. Key Financial Inc boosted its holdings in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the period. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet during the 4th quarter valued at $32,000. Grove Bank & Trust lifted its position in shares of Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 328 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Zimmer Biomet in the second quarter worth $37,000. Finally, Basepoint Wealth LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at $38,000. Institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZBH. Stifel Nicolaus dropped their price objective on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 29th. Leerink Partners began coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 price objective for the company. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $82.46 on Monday. The stock has a market cap of $15.95 billion, a P/E ratio of 21.42, a PEG ratio of 1.90 and a beta of 0.47. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The business’s 50-day moving average price is $87.96 and its two-hundred day moving average price is $90.65. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.Zimmer Biomet’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.